Revenues Not Telling The Story For Guangdong Topstar Technology Co., Ltd. (SZSE:300607) After Shares Rise 29%

Simply Wall StFeb 25 17:27 ET

Here's Why Guangdong Topstar Technology (SZSE:300607) Has A Meaningful Debt Burden

Simply Wall StFeb 18 22:24 ET

Retail Investors Invested in Guangdong Topstar Technology Co., Ltd. (SZSE:300607) Copped the Brunt of Last Week's CN¥1.6b Market Cap Decline

Simply Wall StJan 28 22:12 ET

Guangdong Topstar Technology (300607.SZ): Five-axis linkage CNC machine tools can be used for processing complex spatial structures of components such as humanoid robot arm Brackets, thigh Brackets, and hip Brackets.

On January 20, Gelonghui reported that Guangdong Topstar Technology (300607.SZ) stated on the investor interaction platform that the five-axis CNC machine tools can be used for the processing of complex spatial structures of components such as humanoid robot arm brackets, thigh brackets, and hip joint brackets.

Gelonghui FinanceJan 20 02:19 ET

Once the largest business, now it has become a "burden" on performance. Guangdong Topstar Technology expects to report its first loss since going public | Interpretations.

①Due to the halving of revenue from the formerly largest business, resulting in a loss of approximately 0.2 billion yuan and the recognition of impairment losses, the Robot Concept stock Guangdong Topstar Technology may experience its first loss since going public last year. ②The company stated that significantly shrinking the scale of the Asia Vets Energy and Environmental Management System business has a substantial impact on Net income. ③In the future, Guangdong Topstar Technology will continue to focus on developing business related to robots, CNC machine tools, DKM Injection Machine, and other product categories.

cls.cnJan 16 10:50 ET

January 17 A-shares investment warning highlights︱ *ST Baoxin: Received a preliminary notice of the proposed termination of the company’s Stocks listing; LONGi Green Energy Technology: Expected loss of 8.2 billion yuan to 8.8 billion yuan for the year 202

Zhejiang Orient Gene Biotech: Expected loss of 0.485 billion yuan to 0.535 billion yuan for the year 2024.

Gelonghui FinanceJan 16 08:57 ET